|
Press Releases |
|
|
|
Wednesday, September 8, 2021 |
|
阿诺医药宣布AN2025、AN0025与atezolizumab三联治疗晚期实体瘤1a期临床在美国完成首例患者给药 |
阿诺医药,一家专注于肿瘤治疗领域的创新型全球生物制药公司,今日宣布其口服泛PI3K抑制剂buparlisib(AN2025)、口服EP4拮抗剂(AN0025)与PD-L1抑制剂atezolizumab(阿替利珠单抗)三联疗法在晚期/转移性实体瘤患者中开展的Ia期临床试验已于美国成功完成首例患者给药。 more info >> |
|
阿諾醫藥宣佈AN2025、AN0025與atezolizumab三聯治療晚期實體瘤1a期臨床在美國完成首例患者給藥 |
阿諾醫藥,一家專注於腫瘤治療領域的創新型全球生物製藥公司,今日宣佈其口服泛PI3K抑制劑buparlisib(AN2025)、口服EP4拮抗劑(AN0025)與PD-L1抑制劑atezolizumab(阿替利珠單抗)三聯療法在晚期/轉移性實體瘤患者中開展的Ia期臨床試驗已于美國成功完成首例患者給藥。 more info >> |
|
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors |
Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025 (buparlisib, oral pan-PI3K inhibitor), AN0025 (oral EP4 antagonist) and atezolizumab (PD-L1 inhibitor) in patients with locally advanced/metastatic tumors. more info >> |
|
Thursday, July 15, 2021 |
|
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures |
Adlai Nortye Ltd. (hereinafter referred to as "Adlai Nortye"), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of $100 million Series D financing round. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Shaping the Future of Technology with AI Everywhere Take Center Stage at the 13th Big CIO Show
May 10, 2024 20:55 HKT/SGT
|
|
|
DOCOMO to Launch "NTT DOCOMO GLOBAL" for Global Expansion
May 10, 2024 18:13 JST
|
|
|
Japan Energy Summit and Exhibition Hosts and Sponsors Demonstrate the Importance of Accelerating Decarbonisation
May 10, 2024 16:04 HKT/SGT
|
|
|
Pertamina International Shipping (PIS) Welcomes 2 VLGC Tankers to Its Fleet, Takes Top-Tier Position in ASEAN LPG Transport
May 10, 2024 16:00 HKT/SGT
|
|
|
Q2 Metals Announces Assay Results from Its 2024 Winter Drill Program at the Mia Lithium Property, James Bay Territory, Quebec, Canada
May 10, 2024 15:09 HKT/SGT
|
|
|
三菱重工など、電力系統の混雑緩和を実現するシステムのフィールド実証を開始
May 10, 2024 11:50: JST
|
|
|
Speculation Swirls: ESR (01821.HK) Progresses in Privatization Talks Led by Warburg Pincus
May 10, 2024 11:26 HKT/SGT
|
|
|
Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku"
May 10, 2024 12:20 JST
|
|
|
InfoComm Asia 2024 "Asia's International Pro AV Exhibition" Returns to Thailand
May 10, 2024 10:30 HKT/SGT
|
|
|
好事將近?市傳ESR(01821.HK)第一大股東有意溢價最多60%提私有化
May 10, 2024 10:09 HKT/SGT
|
|
|
BLUETTI Unlocks Special Mother's Day Offerings, Perfect Gift Ideas for Moms
May 10, 2024 10:00 HKT/SGT
|
|
|
AGILON HEALTH (NYSE: AGL) INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Agilon Health Investors of a Class Action Lawsuit and May 20, 2024 Lead Plaintiff Deadline
May 10, 2024 08:33 HKT/SGT
|
|
|
SSR MINING (SSRM) INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies SSR Mining Investors of a Class Action Lawsuit and May 17, 2024 Lead Plaintiff Deadline
May 10, 2024 08:26 HKT/SGT
|
|
|
CHEMOURS (NYSE: CC) ALERT: Kaplan Fox & Kilsheimer LLP Reminds Investors of Class Action Lawsuit and May 20, 2024 Lead Plaintiff Deadline
May 10, 2024 08:20 HKT/SGT
|
|
|
DOXIMITY (NYSE: DOCS) ALERT: Kaplan Fox & Kilsheimer LLP Reminds Investors of Class Action Lawsuit and June 17, 2024 Lead Plaintiff Deadline
May 10, 2024 08:13 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|